Companies ›Healthcare ›OMER.O

OMER.O — NASDAQ Pharmaceuticals

Omeros Corp

$12,46

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

768,4M USD

P/E

7,0x

EV / Rev

—

Div yield

—

Op margin

-212,6 %

ROE

114,3 %

Net margin

-187,0 %

Debt / equity

-1,96

Beta

—

52w range

—

Volume

Day range

—

Prev close

$9,79

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Omeros Corp is a biopharmaceutical company focused on the discovery and development of novel therapeutics, primarily generating revenue from the commercialization of its approved product, Otezla, while incurring significant operating losses due to ongoing research and development activities.

Business. Omeros Corp (OMER.O) is a pharmaceutical company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification85 %

SectorHealth Care

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY4 analysts

2 buy2 hold0 sell

Avg 12m price target44,00

Analyst recommendations

4 analysts · consensus Buy

Buy2

Hold2

Sell0

12-month price target

44,00

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

4 analysts · indicative

Ownership→

UBS Financial Services, Inc.

largest disclosed fund holder

Profitability→

114,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning OMER.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to OMER.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Omeros Corp (OMER.O) is a pharmaceutical company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification85 %

SectorHealth Care

Industry groupPharmaceuticals

AI synthesis

GENERATED

— missing data

Key takeaways

Omeros Corp has negative total equity of -120.8 million USD and high long-term debt of 236.3 million USD, creating a fragile balance sheet.
The company is unprofitable with a net loss of 138.1 million USD and negative operating cash flow of 100.1 million USD.
Analysts maintain a mean price target of 44.00 USD, implying significant upside from the current price of 9.83 USD.
Liquidity risk is medium due to low cash reserves of 10.5 million USD relative to debt obligations.
Dilution risk is currently low, but the negative equity position may require future capital raises.
The EV/Revenue multiple of 11.27 reflects high market expectations for future growth despite current losses.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-05-13

Q1 2026 · Quarter highlights

Open report →

Revenue $9.9M; Operating income +50,2% YoY.

Revenue$9.9M

Operating income-$17.4M+50,2 % YoY

Net income$56.1M+267,5 % YoY

Free cash flow$51.5M+238,0 % YoY

EPS—

Operating cash flow-$14.5M+59,5 % YoY

Financials

Income statement

Revenue$9.9M

Gross profit$9.3M

Operating income-$17.4M

Net income$56.1M

Margins

Gross margin94.1%

Operating margin-176.1%

Net margin566.7%

FCF margin520.4%

Balance sheet

Total assets$286.2M

Total liabilities$349.5M

Total equity-$63.3M

Cash & equivalents$1.9M

Long-term debt$298.6M

Cash flow

Operating cash flow-$14.5M

CapEx$0.00

Free cash flow$51.5M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue $9.9M
▍Operating income +50,2% YoY
▍Net income +267,5% YoY
▍Free cash flow +238,0% YoY
▍Net margin 566.7%

Valuation TTM

Market price

$12,46

Market cap

$606.2M

Enterprise valueⓘ

$832.0M

P/Eⓘ

7.0x

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

-$225.8M

Current ratioⓘ

—

Debt / equityⓘ

-2.0

ROAⓘ

-76.3%

ROEⓘ

1.1%

Cash conversionⓘ

72.0%

CapEx / revenueⓘ

0.4%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships2 disclosed relationships · 2 types · extracted from filings & disclosures

Suppliers1

LONZA GROUP AGLON.NLBSupplier98%Source ↗

Partners1

Daiichi Sankyo Co Ltd4568.TPartner98%Source ↗

Supply chain

Vendors → OMER ↔ Partners → Customers · click any node to drill

2 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,04

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-07-27 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,04
Revenue	—no estimate	—no estimate	68,0M USD
Operating income	—no estimate	—no estimate	-70,6M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution4 analysts

Strong buy1

Buy1

Hold2

Sell0

Strong sell0

12-month price target$44,00 · Median $44,00

Low $33,00High $55,00

Operating income · consensus-70,6M USD

EPS surprise

−42,9 %

reported vs consensus · miss

Revenue surprise

−100,0 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$33,00

Mean$44,00

Median$44,00

High$55,00

Spot$12,46

+253.1 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin-212,6 %Bottom quartile

Net Margin-187,0 %Bottom quartile

ROE114,3 %Best in class

Capex / Rev0,4 %Above P75

D/E-1,96Best in class

Cash Conv0,72Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 877 500 sh3 exercises · 10 grants10 insiders

Demopulos Gregory A MDDirector, Chairman, CEO & President · Stock Option (right to buy) → Common StockAcquired 1 000 000 @ $9,84grant · 2026-07-22
Borges David J.VP, Finance & CAO · Stock Option (right to buy) → Common StockAcquired 105 000 @ $9,84grant · 2026-07-22
Cancelmo Peter BVP, General Counsel · Stock Option (right to buy) → Common StockAcquired 105 000 @ $9,84grant · 2026-07-22
Bumol Thomas F.Director · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $10,28grant · 2026-06-18
Cable Thomas J.Director · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $10,28grant · 2026-06-18
Perkinson Diana T.Director · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $10,28grant · 2026-06-18
Shah RajivDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $10,28grant · 2026-06-18
Demopulos Peter A MDDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $10,28grant · 2026-06-18
HANISH ARNOLD CDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $10,28grant · 2026-06-18
Hood Leroy E. MD PhDDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $10,28grant · 2026-06-18
Cable Thomas J.Director · Stock Option (Right to Buy) → Common StockDisposed 7 500 @ $10,84exercise · 2026-05-22
Demopulos Gregory A MDDirector, Chairman, CEO & President · Stock option (right to buy) → Common stockDisposed 400 000 @ $10,27exercise · 2026-02-18
Borges David J.VP, Finance & CAO · Stock Option (right to buy) → Common StockDisposed 30 000 @ $3,06exercise · 2026-01-13

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Reference data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Enterprise Value
market_cap - net_cash
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Market Price
input from market-data provider (delayed close or quote-shim mid)
Capex To Revenue
capital_expenditure / revenue

Source documents

OMEROS CORPORATION Market data — financials · 2026-07-27
Omeros Corp Market data — analyst estimates · 2026-07-27
Omeros Corp Market data — ESG · 2026-07-27
Omeros Corp HA canonical relationships · 2026-07-27

Ownership & reference

Top holders

UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$25M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$19M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$69M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$6M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$6M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$20M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$2M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$17M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$2M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$2M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$2M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$1M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$2M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$3M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net selling0 buys · 3 sellsnet -$838K3 insiders · last 365d

Cable Thomas J.Director · Common StockSold 7 500 @ $11,61$87K · 2026-05-22
Cable Thomas J.Director · Common StockOther 7 500 @ $10,84$81K · 2026-05-22
Demopulos Gregory A MDDirector, Chairman, CEO & President · Common stockOther 400 000 @ $10,27$4,1M · 2026-02-18
Demopulos Gregory A MDDirector, Chairman, CEO & President · Common stockOther 357 678 @ $11,93$4,3M · 2026-02-18
Borges David J.VP, Finance & CAO · Common stockSold 30 000 @ $12,31$369K · 2026-01-13
Borges David J.VP, Finance & CAO · Common stockOther 30 000 @ $3,06$92K · 2026-01-13
Borges David J.VP, Finance & CAO · Common stockSold 30 000 @ $12,72$382K · 2026-01-12
Demopulos Gregory A MDDirector, Chairman, CEO & President · Common StockOther 600 000 · 2025-10-13
Demopulos Gregory A MDDirector, Chairman, CEO & President · Common StockOther 300 000 · 2025-10-13

Short positioning

15.1Mshares short-0.3% vs prior

11.85days to cover

38.7%short of daily vol

4.9Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

OMER.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorSuppliersPartners

Evidence & claims

From filings & derived data

Pre-tax income (annual): USD -2.8MUnknown
EPS (basic) (annual): USD-PER-SHARES -0Unknown
Long-term debt (annual): USD 87.9MUnknown
Current liabilities (annual): USD 78.06MUnknown
Operating income (annual): USD -122.8MUnknown
EPS (diluted) (annual): USD-PER-SHARES -0Unknown
R&D expense (annual): USD 81.3MUnknown
Operating cash flow (annual): USD -116.09MUnknown
Shares outstanding (annual): 71.67MUnknown
Shareholders' equity (annual): USD -121.23MUnknown
Total assets (annual): USD 325.63MUnknown
Current assets (annual): USD 215.67MUnknown
Cash & equivalents (annual): USD 9.66MUnknown
Capex (annual): USD 65KUnknown
EPS (diluted) (annual): USD-PER-SHARES -3Unknown
R&D expense (annual): USD 119.52MUnknown
Cash & equivalents (annual): USD 3.4MUnknown
Shares outstanding (annual): 58.04MUnknown
Operating cash flow (annual): USD -148.8MUnknown
EPS (basic) (annual): USD-PER-SHARES -3Unknown
Long-term debt (annual): USD 164.9MUnknown
Capex (annual): USD 165KUnknown
Total assets (annual): USD 277.08MUnknown
Current assets (annual): USD 134.12MUnknown

Showing 24 of 28 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-22INSIDERCancelmo Peter B acquired 105.0k sh Stock Option (right to buy) — VP, General Counsel

2026-07-22INSIDERDemopulos Gregory A MD acquired 1.00M sh Stock Option (right to buy) — Director, Chairman, CEO & President

2026-07-22INSIDERBorges David J. acquired 105.0k sh Stock Option (right to buy) — VP, Finance & CAO

2026-06-18 00:00 UTCINSIDER7 insider transactions — 2026-06 7 derivative

2026-06-18FILINGFORM 8-K →

2026-06-18INSIDERShah Rajiv acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERBumol Thomas F. acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERCable Thomas J. acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERDemopulos Peter A MD acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERHANISH ARNOLD C acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERHood Leroy E. MD PhD acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-06-18INSIDERPerkinson Diana T. acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-05-22 00:00 UTCINSIDER3 insider transactions — 2026-05 · $168k gross 1 derivative

2026-05-22INSIDERCable Thomas J. sold 7.5k sh — Director ~$87k

2026-05-22INSIDERCable Thomas J. transacted 7.5k sh — Director ~$81k

2026-05-22INSIDERCable Thomas J. disposed of 7.5k sh Stock Option (Right to Buy) — Director

2026-05-13 16:02 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 9.9M · Net USD 56.1M

2026-05-13FILINGFORM 10-Q →

2026-05-13FILINGFORM 8-K →

2026-04-30FILINGProxy statement →

2026-03-31 16:07 UTCEARNINGSQuarterly results — Q4 2025 Net USD 86.5M

2026-03-31 16:07 UTCEARNINGSAnnual results — FY 2026 Net USD -3.4M

2026-03-31FILINGFORM 10-K →

2026-03-31FILINGFORM 8-K →

2026-02-18 00:00 UTCINSIDER3 insider transactions — 2026-02 · net sell $159k 1 derivative

2026-02-18INSIDERDemopulos Gregory A MD transacted 400.0k sh — Director, Chairman, CEO & President ~$4.11M

2026-02-18INSIDERDemopulos Gregory A MD transacted 357.7k sh — Director, Chairman, CEO & President ~$4.27M

2026-02-18INSIDERDemopulos Gregory A MD disposed of 400.0k sh Stock option (right to buy) — Director, Chairman, CEO & President

2026-01-13 00:00 UTCINSIDER4 insider transactions — 2026-01 · net sell $659k 1 derivative

2026-01-13INSIDERBorges David J. sold 30.0k sh — VP, Finance & CAO ~$369k

2026-01-13INSIDERBorges David J. transacted 30.0k sh — VP, Finance & CAO ~$92k

2026-01-13INSIDERBorges David J. disposed of 30.0k sh Stock Option (right to buy) — VP, Finance & CAO

2026-01-12INSIDERBorges David J. sold 30.0k sh — VP, Finance & CAO ~$382k

2026-01-07FILINGFORM 8-K →

2025-12-29FILINGFORM 8-K →

2025-12-01FILINGFORM 8-K →

2025-11-14FILING424B5 filing →

2025-11-13 16:11 UTCEARNINGSQuarterly results — Q3 2025 Net USD -30.9M

2025-11-13FILINGFORM 10-Q →

Showing the 40 most recent of 55 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation TTM

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread